Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: No clinically relevant impact of a birth dose of hepatitis B vaccine

International Journal of Infectious Diseases

Volumn 15, Issue 1, 2011, Pages

  Gentile, Angela ^a   Umido, Veronica ^a   Czerniuk, Paola ^a   Nacul, Josefina ^a   Seigelchifer, Mauricio ^b   Hilbert, Anne Katrin ^c   Yela, Ursula ^d   Herzog, Christian ^d   Aeberhard, Ursula ^d   Spyr, Christian ^d  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b PC Gen SA   (Argentina)

^c GSK Marburg Vaccines and Diagnostics   (Germany)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Hepatitis B; Immunogenicity; Pentavalent vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B VACCINE; VIRUS ANTIGEN;

ANTIBODY TITER; ARTICLE; CHILD CARE; COMPARATIVE STUDY; CRYING; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; IRRITABILITY; MALE; NORMAL HUMAN; SEROCONVERSION; SIDE EFFECT; SOMNOLENCE; VOMITING;

ADMINISTRATION, ORAL; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CORYNEBACTERIUM DIPHTHERIAE; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; TETANUS TOXIN; VACCINATION;

EID: 78650876324     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.09.004     Document Type: Article

References (34)

1. World Health Organization. Pertussis vaccine-WHO position paper. Wkly Epidemiol Rec 2010;85:385-400.
2. Halsey N., Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull World Health Organ 1985, 63:1151-1169.
3. Taranger J., Trollfors B., Knutsson N., Sundh V., Lagergard T., Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 1999, 18:884-891.
4. World Health Organization Expanded Programme on Immunization: Global Advisory Group-Part I. Wkly Epidemiol Rec 1992, 67:11-15.
5. World Health Organization WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 81:445-452.
6. World Health Organization. Introducing Haemophilus influenzae type b (Hib) conjugate vaccine into national immunization services. WHO Fact Sheet 2001 (WHO/V&B/01.29). Geneva: World Health Organization; 2001. Available at: (accessed 15.12.09). http://www.who.int/vaccines-documents/DocsP0F01/www599.pdf.
7. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946-2950.
8. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
9. Win K.M., Aye M., Htay-Htay H., Safary A., Bock H. Comparison of separate and mixed administration of DTPw-HBV and Hib vaccines: immunogenicity and reactogenicity profiles. Int J Infect Dis 1997, 2:79-84.
10. Riedemann S., Reinhardt G., Jara J., Rios R., Wenzel M.S., Willems P., et al. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. Int J Infect Dis 2002, 6:215-222.
11. Faingezicht I., Avila-Aguerro M.L., Cervantes Y., Fourneau M., Clemens S.A. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica 2002, 12:247-257.
12. Gatchalian S., Reyes M., Bernal N., Lefevre I., David M.P., Han H.H., et al. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin 2005, 1:198-203.
13. Lopez P., Rubiano L., del Pilar Rubio M., David M.P., Safary A. Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to Colombian infants after a birth dose of hepatitis B vaccine. Expert Rev Vaccines 2002, 1:277-283.
14. World Health Organization. United Nations prequalified vaccines. Geneva: World Health Organization; 2009. Available at: (accessed 29.08.10). http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html.
15. Hla Hla K., Thein S.A., Aye A., Han H.H., Bock H.L., David M.P., et al. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type b vaccine. Pediatr Infect Dis J 2006, 25:706-712.
16. Kanra G., Kara A., Demiralp O., Contorni M., Hilbert A.K., Spyr C., et al. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants. Hum Vaccin 2006, 2:155-160.
17. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children, and adolescents. MMWR 2005; 54(RR-16):1-23.
18. Lee C.Y., Huang L.M., Chang M.H., Hsu C.Y., Wu S.J., Sung J.L., et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991, 10:299-303.
19. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989, 261:3278-3281.
20. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Chitinand S., et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990, 8(Suppl):S56-S59.
21. Poovorawan Y., Sanpavat S., Pongpunglert W., Chumdermpadetsuk S., Sentrakul P., Vandepapeliere P., et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992, 11:816-821.
22. Pichichero M.E., Blatter M.M., Reisinger K.S., Harrison C.J., Johnson C.E., Steinhoff M.C., et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002, 21:854-859.
23. Greenberg D.P., Wong V.K., Partridge S., Howe B.J., Ward J.I. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. Pediatr Infect Dis J 2002, 21:769-777.
24. Nolan T., Hogg G., Darcy M.A., Skeljo M., Carlin J., Boslego J. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Vaccine 2001, 19:2127-2137.
25. Cheng H.K., Rajadurai V.S., Amin Z., Sriram B., Yee M.F., Han H.H., et al. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Southeast Asian J Trop Med Public Health 2004, 35:685-692.
26. Deinhardt F., Zuckerman A.J. Immunization against hepatitis B: report on a WHO meeting on viral hepatitis in Europe. J Med Virol 1985, 17:209-217.
27. von Hunolstein C., Aggerbeck H., Andrews N., Berbers G., Fievet-Groyne F., Maple P.A., et al. European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays. Vaccine 2000, 18:3287-3296.
28. Galazka AM. Expanded Programme on Immunization: the immunological basis for immunization. WHO Document WHO/EPI/GEN/93.13, Module 3: Tetanus; Geneva: World Health Organization; 1993. Available at: (accessed 15.12.09). http://www.who.int/vaccines-documents/Docs-PDF-IBI-e/mod3_e.pdf.
29. Mertsola J., Ruuskanen O., Kuranen T., Viljanen M.K. Serologic diagnosis of pertussis: comparison of enzyme-linked immunosorbent assay and bacterial agglutination. J Infect Dis 1983, 147:252-257.
30. Mariani M., Luzzi E., Proietti D., Mancianti S., Casini D., Costantino P., et al. A competitive enzyme-linked immunosorbent assay for measuring the levels of serum antibody to Haemophilus influenzae type b. Clin Diagn Lab Immunol 1998, 5:667-674.
31. Michael Marcy S., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22:551-556.
32. Bonhoeffer J., Vermeer P., Halperin S., Kempe A., Music S., Shindman J., et al. Brighton Collaboration Persistent Crying Working Group. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22:586-591.
33. Product Information Australia for Hiberix®: Haemophilus influenzae type b (Hib) vaccine. Issue 4, last amended 9 April 2009. Rixensart, Belgium: GlaxoSmithKline Biologicals S.A.; 2009.
34. Mahoney F.J., Kane M. Hepatitis B vaccine. Vaccines. 1999, 158. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).